Calcium survey
This article was originally published in The Tan Sheet
Executive Summary
OTCs comprised 33% of osteoporosis treatments purchased during 12 months ended June 30, a consumer survey conducted by NPD PharmTrends shows. Overall, 7% of U.S. consumers use drugs or supplements to treat and prevent osteoporosis, up from 4% in prior-year period. Dollar share for calcium supplements - including Mission Pharmacal's Citracal, Whitehall-Robins' Caltrate and SmithKline Beecham's Oscal brands - totals 5.1%, compared to 82% for top five Rx drugs, PharmTrends notes. Information Resources, Inc. (Chicago) lists total food, drug and mass calcium sales at $361.5 mil. for the 52 weeks ended Nov. 12